pancreatic cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age range: 18 to 75 years old (inclusive); 2. Individuals with behavioral capacity who voluntarily participate in this clinical study and sign the Informed Consent Form (ICF); 3. Confirmed as pancreatic cancer through histopathology or cytology; or suspected of having pancreatic cancer based on imaging or clinical findings, with plans to perform tumor resection or tissue biopsy within 60 days after enrollment, and the patient must agree to provide sufficient and appropriate tumor tissue samples (formalin-fixed, paraffin-embedded samples) for pathological testing by the research center after surgery; 4. The patient has not received the following treatments for the tumor: radiotherapy (including brachytherapy), systemic anti-tumor drugs (chemotherapy, small molecule targeted drugs, monoclonal antibody drugs, etc.), or other experimental treatments in clinical research.
Exclusion criteria
Exclusion criteria: 1. Incorporate other patients with clearly diagnosed malignant tumors; 2. Individuals with uncontrolled severe infections, or those accompanied by other serious illnesses; 3. Patients with an expected survival period of <=3 months; 4. Pregnant or lactating patients, as well as childbearing-age patients who refuse to take appropriate contraceptive measures during the trial; 5. Patients whom the researchers judged as unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Medication Safety;PET Imaging Characteristics; | — |
Secondary
| Measure | Time frame |
|---|---|
| The correlation between PET imaging and Claudin 18.2 expression levels as measured by immunohistochemistry (IHC);Diagnostic Efficacy; | — |
Countries
China
Contacts
Tianjin Medical University Cancer Institute and Hospital